|
You are here: Home: BCU 7|2002: A CME Audio Series and Activity
Breast Cancer Update: A CME Audio Series and
Activity
STATMENT OF NEED / TARGET AUDIENCE
Breast cancer is one of the most rapidly evolving fields in medical
oncology. Published results from a plethora of ongoing clinical
trials lead to the continuous emergence of new therapeutic agents
and changes in the indications for existing treatments. In order
to offer optimal patient care — including the option of clinical
trial participation — the practicing medical oncologist must
be well informed of these advances.
To bridge the gap between research and patient care, Breast Cancer
Update utilizes one-on-one discussions with leading oncology investigators.
By providing access to the latest research developments and expert
perspectives, this CME program assists medical oncologists in the
formulation of up-to-date clinical management strategies.
Issue 7, 2002 of Breast Cancer Update consists of discussions with
four oncology research leaders on a variety of important issues,
including the role of trastuzumab in treating HER2-positive metastatic
disease, the toxicities of trastuzumab and trastuzumab in combination
with other chemotherapeutic regimens, the sequencing of treatment
for the elderly patient, current clinical trials for the elderly,
adjuvant hormonal therapy and the management of the patient at high
risk for breast cancer.
EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should
be able to:
- Evaluate the survival advantage observed in the trastuzumab
pivotal trial in order to determine the importance of considering
earlier treatment with trastuzumab in patients with HER2-positive
metastatic breast cancer.
- Distinguish among the various approaches to sequencing and
combining therapeutic agents in order to define the most efficacious
and least toxic treatment regimens for patients with metastatic
disease.
- Understand the risks and benefits of combining chemotherapy
with trastuzumab in order to select the most effective, least
toxic regimens for HER2-positive patients.
- Apply the findings of the 2002 ASCO technology assessment to
determine the appropriateness of using aromatase inhibitors as
adjuvant therapy for patients with ER/PR receptor–positive
breast cancer.
- Identify and manage patients who are at high risk for developing
breast cancer using the findings from the 2002 ASCO technology
assessment of pharmacologic interventions for breast cancer risk
reduction.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance
with the Essential Areas and Policies of the Accreditation Council
for Continuing Medical Education (ACCME) through the joint sponsorship
of the Postgraduate Institute for Medicine and NL Communications,
Inc. The Postgraduate Institute for Medicine is accredited by the
ACCME to provide continuing medical education for physicians.
DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this
educational activity for a maximum of 3 hours in category 1 credit
toward the AMA Physician's Recognition Award. Each physician should
claim only those hours of credit that he/she actually spent in the
activity.
FACULTY DISCLOSURE STATEMENTS
The Postgraduate Institute for Medicine has a conflict of interest
policy that requires course faculty to disclose any real or apparent
commercial financial affiliations related to the content of their
presentations/materials. It is not assumed that these financial
interests or affiliations will have an adverse impact on faculty
presentations; they are simply noted in this supplement to fully
inform participants.
|
